Serum lnc34a is a potential prediction biomarker for bone metastasis in hepatocellular carcinoma patients

BMC Cancer

Zuo-Lin Xiang¹  Jie Ma²  Zhao-Chong Zeng²  Ping Yang²  Hao Niu²  Li Zhang²  Bao-Ying Yuan² 

[1] Department of Radiation Oncology, Shanghai East Hospital, Tongji University School of Medicine;Department of Radiation Oncology, Zhongshan Hospital, Fudan University;

关键词: Hepatocellular carcinoma;    Bone metastasis;    Serum;    lnc34a;   

DOI  :  10.1186/s12885-021-07808-6

来源: DOAJ

【 摘 要 】

Abstract Background Early screening and intervention therapies are crucial to improve the prognosis of hepatocellular carcinoma (HCC) patients with bone metastasis. We aimed to identify serum lncRNA as a prediction biomarker in HCC bone metastasis. Methods The expression levels of lnc34a in serum samples from 157 HCC patients were detected by quantitative real-time polymerase chain reaction (PCR). Univariate analysis and multivariate analysis were performed to determine statistically significant variables. Results Expression levels of lnc34a in serum from HCC patients with bone metastasis were significantly higher than those without bone metastasis. The high expressions of lnc34a, vascular invasion and Barcelona Clinic Liver Cancer (BCLC) stage were associated with bone metastasis by analysis. Moreover, lnc34a expression was specifically associated with bone metastasis rather than lung or lymph node metastasis in HCC. Conclusions High serum lnc34a expression was a independent risk factor for developing bone metastasis in HCC.

【 授权许可】

Unknown